Cytokinetics has initiated a Phase I clinical trial with CK-1827452, a small-molecule
activator of cardiac myosin, for the treatment of patients with heart failure.
CK-1827452 is the first clinical drug candidate to arise from the company's
cardiac myosin activator program.
The clinical trial is a double-blind, randomized, placebo-controlled trial being conducted to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of CK-1827452 in normal healthy volunteers. This dose-escalation trial is designed to identify the maximally tolerated dose of a six-hour intravenous infusion of CK-1827452. The effect of CK-1827452 on the left ventricular function of these healthy volunteers will be evaluated using serial echocardiograms.